全文获取类型
收费全文 | 8610篇 |
免费 | 42篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 263篇 |
儿科学 | 42篇 |
妇产科学 | 135篇 |
基础医学 | 1023篇 |
口腔科学 | 265篇 |
临床医学 | 1600篇 |
内科学 | 902篇 |
皮肤病学 | 16篇 |
神经病学 | 107篇 |
特种医学 | 498篇 |
外科学 | 1960篇 |
综合类 | 106篇 |
预防医学 | 609篇 |
眼科学 | 153篇 |
药学 | 301篇 |
中国医学 | 1篇 |
肿瘤学 | 686篇 |
出版年
2023年 | 2篇 |
2022年 | 3篇 |
2021年 | 7篇 |
2020年 | 3篇 |
2019年 | 5篇 |
2018年 | 4篇 |
2017年 | 8篇 |
2016年 | 9篇 |
2015年 | 17篇 |
2014年 | 23篇 |
2013年 | 15篇 |
2012年 | 339篇 |
2011年 | 675篇 |
2010年 | 339篇 |
2009年 | 33篇 |
2008年 | 498篇 |
2007年 | 690篇 |
2006年 | 696篇 |
2005年 | 685篇 |
2004年 | 805篇 |
2003年 | 805篇 |
2002年 | 868篇 |
2001年 | 548篇 |
2000年 | 736篇 |
1999年 | 385篇 |
1998年 | 152篇 |
1997年 | 40篇 |
1996年 | 31篇 |
1995年 | 19篇 |
1994年 | 27篇 |
1993年 | 45篇 |
1992年 | 5篇 |
1991年 | 10篇 |
1990年 | 5篇 |
1989年 | 12篇 |
1988年 | 12篇 |
1987年 | 25篇 |
1986年 | 8篇 |
1985年 | 12篇 |
1984年 | 5篇 |
1983年 | 7篇 |
1982年 | 14篇 |
1981年 | 5篇 |
1980年 | 5篇 |
1978年 | 8篇 |
1977年 | 4篇 |
1976年 | 8篇 |
1975年 | 5篇 |
1972年 | 3篇 |
1967年 | 1篇 |
排序方式: 共有8667条查询结果,搜索用时 573 毫秒
161.
Batyraliev TA Pershukov IV Niiazova-Karben ZA Preobrazhenskiĭ DV Sercelik A Karaus A Calenici O Guler N Eryonucu B Kadayifci S Ozgul S Akgul F Temamogullari A Demirbas O Sengul H Dogru O Petrakova LV Sidorenko BA 《Kardiologiia》2003,43(8):9-15
BACKGROUND: Although balloon angioplasty and stenting are effective in the treatment of acute myocardial infarction (M1), reduced coronary flow and distal embolization frequently complicate interventions when thrombus is present. Adjunctive treatment with mechanical thrombectomy devices was suggested to reduce these complications. METHODS: We evaluated immediate angiographic, in-hospital and 30-day follow-up clinical outcomes of 185 patients with acute MI and angiographically evident thrombus who were treated with AngioJet rheolytic thrombectomy followed by immediate definitive treatment. RESULTS: Procedural success (residual diameter stenosis <50% and thrombolysis in myocardial infarction [TIMI] flow >2 after final treatment) was 97%. Rheolytic thrombectomy success was achieved in 7% of patients. Subsequent definitive treatment included stenting in 67% and balloon angioplasty alone in 26% of patients. Final TIMI 3 flow was achieved in 89%. AngioJet treatment resulted in mean thrombus area reduction from 69.6 mm(2) at baseline to 17.3 mm(2) post-thrombectomy (p<0.001). Procedural complications included distal embolization (7.6%) and perforation (1.1%). Clinical success (procedure success without major in-hospital cardiac events) rate was 88%, in-hospital mortality - 7.0%. There were no further major adverse events during 30-day follow-up. CONCLUSION: Rheolytic thrombectomy can be performed safely and effectively in patients with acute MI, allowing for immediate definitive treatment of thrombus-containing lesions. 相似文献
162.
Sidorenko BA Preobrazhenskiĭ DV Sharoshina IA Batyraliev TA Pershukov IV Makhmutkhodzhaev SA 《Kardiologiia》2005,45(6):61-70
In a series of papers the authors analyze literature data on the use of cardiac glycosides for long term treatment of chronic heart failure. Data obtained in prospective placebo controlled trial DIG show that digoxin significantly increases mortality of all patients with sinus rhythm and intact left ventricular systolic function (ejection fraction > 45%) and of women with left ventricular systolic dysfunction (ejection fraction < or = 45%). Men with left ventricular systolic dysfunction represent the only category of patients with chronic heart failure in sinus rhythm in whom long term administration of digoxin is justified. Digoxin does not affect mortality of these patients however it reduces requirements in hospitalizations due to worsening of heart failure. 相似文献
163.
High efficacy of aspirin in secondary prevention after myocardial infarction and stroke is well established. However the place of aspirin in primary prevention of coronary heart disease and other cardiovascular diseases remains questionable. Analysis of results of large controlled studies of efficacy and safety of aspirin in high risk subjects shows that low doses of aspirin should be used in men with high risk of coronary heart disease but without main risk factors of stroke. 相似文献
164.
Patients with nonrheumatic atrial fibrillation (n=465, mean age 59.4+/-3.8 years) received controlled therapy for 7.4+/-1.6 years. Group 1 comprised 306 patients with paroxysmal and persistent atrial fibrillation who after restoration of sinus rhythm received antiarrhythmic therapy aimed at prevention of recurrences and repetitive cardioversions. Group 2 consisted of 67 similar patients who did not receive continuous antiarrhythmic therapy. Therapy of patients with persistent atrial fibrillation (group 3, n=92) included heart rate slowing drugs and anticoagulants. Group 1 was characterized by lowest rate of complications and all cause mortality, and best quality of life. There were more nonfatal strokes in group 2. All cause mortality in group 2 was 15% (p<0.05). Highest rate of nonfatal strokes, and deaths due to chronic heart failure was observed in group 3. All cause mortality in this group was 22.8% (p<0.001 vs group 1). 相似文献
165.
KA Hodgkinson SP Connors N Merner A Haywood T‐L Young WJ McKenna B Gallagher F Curtis AS Bassett PS Parfrey 《Clinical genetics》2013,83(4):321-331
To determine the phenotype and natural history of a founder genetic subtype of autosomal dominant arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by a p.S358L mutation in TMEM43. The age of onset of cardiac symptoms, clinical events and test abnormalities were studied in 412 subjects (258 affected and 154 unaffected), all of which occurred in affected males significantly earlier and more often than unaffected males. Affected males were hospitalized four times more often than affected females (p ≤ 0.0001) and died younger (p ≤ 0.001). The temporal sequence from symptoms onset to death was prolonged in affected females by 1–2 decades. The most prevalent electrocardiogram (ECG) manifestation was poor R wave progression (PRWP), with affected males twice as likely to develop PRWP as affected females (p ≤ 0.05). Left ventricular enlargement (LVE) occurred in 43% of affected subjects, with 11% fulfilling criteria for dilated cardiomyopathy. Ventricular ectopy on Holter monitor was common and occurred early: the most diagnostically useful clinical test. No symptom or test could rule out diagnosis. This ARVC subtype is a sex‐influenced lethal arrhythmogenic cardiomyopathy, with a unique ECG finding, LV dilatation, heart failure and early death, where molecular pre‐symptomatic diagnosis has the greatest clinical utility. 相似文献
166.
167.
Role of Chlamydia, mycoplasma and cytomegalovirus infection in the development of coronary artery disease 总被引:1,自引:0,他引:1
Basinkevich AB Shakhnovich RM Martynova VR Kolkova NI Rakovskaia IV Karazhas NV Evseeva LF Dobrovolskiĭ AB Deev AD Noeva EA Ruda MIa 《Kardiologiia》2003,43(11):4-9
AIM: To assess relationship between some infection factors and presence of coronary heart disease. MATERIAL: Patients with myocardial infarction (n=56), unstable angina (n=50), stable angina (n=50) and age - matched controls (n=49). METHODS: Levels of IgG, IgM, IgA antibodies to Chlamydia pneumonia, Chlamydia trachomatis, Chlamydia psittaci, IgG, IgM antibodies to Cytomegalovirus, and also of antibodies and antigen to Mycoplasma pneumoniae were measured in blood serum. RESULTS: Compared with controls patients with coronary heart disease had higher frequency of seropositivity to Chlamydia pneumonia, Mycoplasma pneumonia and Cytomegalovirus (p< 0.05 ) and similar levels of seropositivity to Chlamydia trachomatis and Chlamydia psittaci. Infectious burden (quantity of antibodies per one patient) was significantly higher in patients with myocardial infarction, unstable and stable angina than in controls (1.58, 1.42, 1.41 and 0.95, respectively). CONCLUSION: Our results confirm presence of association between infection and coronary heart disease. 相似文献
168.
169.
170.
Akhmetzianova ÉKh Gaĭnitdinova VV Bakirov AB Bogoroditskaia OA Timershina IR 《Kardiologiia》2012,52(2):41-46
In order to assess effect of If-channel blocker ivabradine on severity of pulmonary hypertension in chronic obstructive pulmonary disease (COPD) we studied 60 patients with III-IV stage COPD. We divided these patients into 2 groups with similar clinical characteristics and therapy. Patients of one of these groups received ivabradine (10 mg/day) for 2 weeks, patients of another served as controls. The use of ivabradine was associated with statistically significant lowering of pulmonary hypertension, heart rate, and increase of exercise tolerance without negative effects on myocardial contractility, electrophysiological parameters, or data of spirometry. 相似文献